Astellas signs $760mm deal for beta-secretase inhibitors; CTS21166 program terminated; entire deal ended
- Includes Royalty or Profit Split Information
- R+D and Marketing-Licensing
- Includes Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.